JNJ-53718678 500 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

HealthyRespiratory Syncytial Virus Infections

Phase 1

A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants

CompletedNCT03696459

Janssen Research & Development, LLCHealthy

Start: 2018-10-02End: 2019-12-13Updated: 2020-02-18

Phase 2

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

CompletedNCT03379675

Janssen Research & Development, LLCRespiratory Syncytial Virus Infections

Start: 2018-02-06End: 2019-12-26Updated: 2025-02-04

Related Papers

A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.

2023-07-0612 citations